Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
I-131-MIP-1466
print preview
bookmark
share with colleague
General Information
Company
Progenics Pharmaceuticals Inc.
Description
Small molecule radiopharmaceutical targeting prostate-specific antigen (KLK3; PSA)
Molecular Target
Mechanism of Action
Latest Stage of Development
Preclinical
Indication
Prostate cancer
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy